Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kruse, Sebastian [VerfasserIn]   i
 Büchler-Schäff, Marleen [VerfasserIn]   i
 Uhl, Philipp [VerfasserIn]   i
 Sauter, Max [VerfasserIn]   i
 Yang, Ruwen [VerfasserIn]   i
 Mier, Walter [VerfasserIn]   i
Titel:Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model
Verf.angabe:Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier & Angelika B. Riemer
Jahr:2019
Jahr des Originals:2018
Teil:volume:8
 year:2019
 number:1
Fussnoten:Published online: 29 October 2018 ; Gesehen am /05.06.2019
Titel Quelle:Enthalten in: OncoImmunology
Ort Quelle:Abingdon : Taylor & Franics, 2012
Jahr Quelle:2019
Band/Heft Quelle:8(2019,1) Artikel-Nummer e1524694, ? Seiten
ISSN Quelle:2162-402X
Abstract:Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages. MHC-humanized mice are valuable tools for the study of therapeutic cancer vaccines - given the availability of a suitable tumor model. Here, we present for the first time an HPV16 tumor model suitable for fully MHC-humanized A2.DR1 mice, PAP-A2 cells, which in contrast to existing HPV16 tumor models allows the exclusive study of HLA-A2- and DR1-mediated immune responses, without any interfering murine MHC-presented epitopes. We used several HPV16 epitopes that were shown to be presented on human cervical cancer cells by mass spectrometry for therapeutic anti-tumor vaccination in the new tumor model. All epitopes were immunogenic when rendered amphiphilic by incorporation into a molecule containing stearic acids. Prophylactic and therapeutic vaccination experiments with the epitope E7/11-19 demonstrated that effective immune responses could be induced with these vaccination approaches in A2.DR1 mice. Interestingly, the combination of E7/11-19 with other immunogenic HPV16 E6/E7 epitopes caused a reduction of vaccine efficacy, although all tested combinations resulted in a survival benefit. In summary, we present the first HPV16 tumor model for exclusive studies of HLA-A2-mediated anti-HPV tumor immune responses and show anti-tumor efficacy of minimal epitope vaccines.
DOI:doi:10.1080/2162402X.2018.1524694
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1080/2162402X.2018.1524694
 DOI: https://doi.org/10.1080/2162402X.2018.1524694
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:A2.DR1
 Cancer immunotherapy
 HLA-humanized mouse model
 human papillomavirus (HPV)
 PAP-A2
 therapeutic vaccination
K10plus-PPN:1666836508
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68396571   QR-Code
zum Seitenanfang